A randomized trial (Irish Clinical Oncology Research Group 97-01) comparing short versus protracted neoadjuvant hormonal therapy before radiotherapy for localized prostate cancer

International Journal of Radiation Oncology Biology Physics

Volumn 81, Issue 1, 2011, Pages 35-45

  Armstrong, John G ^a   Gillham, Charles M ^a   Dunne, Mary T ^a   Fitzpatrick, David A ^a   Finn, Marie A ^a   Cannon, Mairín E ^a   Taylor, Judy C ^a   O'Shea, Carmel M ^a   Buckney, Steven J ^a   Thirion, Pierre G ^a  

^a ST LUKE S HOSPITAL   (Ireland)

Author keywords

Biochemical failure; Neoadjuvant hormonal therapy; Prostate cancer; Radiotherapy; Randomized clinical trial

Indexed keywords

BIOCHEMICAL FAILURE; CLINICAL ONCOLOGY; COMPUTED TOMOGRAPHY; CUMULATIVE PROBABILITIES; FAILURE-FREE SURVIVAL; GLEASON SCORES; LOCALIZED PROSTATE CANCER; LONG-TERM OUTCOME; NEOADJUVANT HORMONAL THERAPY; ONE-FACTOR; OVERALL SURVIVAL; PROSTATE CANCERS; PROSTATE SPECIFIC ANTIGEN; RANDOMIZED CLINICAL TRIALS; RANDOMIZED TRIAL; RESEARCH GROUPS; RISK FACTORS; STATISTICALLY SIGNIFICANT DIFFERENCE;

COMPUTERIZED TOMOGRAPHY; RADIOTHERAPY; TOMOGRAPHY;

DISEASES;

PROSTATE SPECIFIC ANTIGEN;

ADJUVANT THERAPY; ADULT; AGED; ARTICLE; BONE SCINTISCANNING; CANCER RADIOTHERAPY; CANCER STAGING; CANCER SURVIVAL; COMPARATIVE STUDY; COMPUTER ASSISTED TOMOGRAPHY; FOLLOW UP; GLEASON SCORE; HORMONAL THERAPY; HUMAN; MAJOR CLINICAL STUDY; NEOADJUVANT HORMONAL THERAPY; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; PROSTATE CANCER; RANDOMIZED CONTROLLED TRIAL; RISK FACTOR; SURVIVAL RATE; SURVIVAL TIME;

ADENOCARCINOMA; AGED; ANDROGEN ANTAGONISTS; ANTINEOPLASTIC AGENTS, HORMONAL; DISEASE-FREE SURVIVAL; DRUG ADMINISTRATION SCHEDULE; FLUTAMIDE; HUMANS; MALE; MIDDLE AGED; NEOADJUVANT THERAPY; NEOPLASM STAGING; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; RADIOTHERAPY, CONFORMAL; RISK FACTORS; TREATMENT OUTCOME; TRIPTORELIN;

EID: 79961126167     PISSN: 03603016     EISSN: 1879355X     Source Type: Journal    
DOI: 10.1016/j.ijrobp.2010.04.065     Document Type: Article

References (40)

1. M. Bolla, L. Collette, and L. Blank Long-term results with immediate androgen suppression and external irradiation in patients with locally advanced prostate cancer (an EORTC study): A phase III randomised trial Lancet 360 2002 103 106
2. M. Bolla, T.M. de Reijke, and G. van Tienhoven Duration of androgen suppression in the treatment of prostate cancer N Engl J Med 360 2009 2516 2527
3. M. Bolla, L. Collette, and G. Van Tienhoven Ten year results of long term adjuvant androgen deprivation with goserelin in patients with locally advanced prostate cancer treated with radiotherapy: A phase III EORTC study [Abstract] Int J Radiat Oncol Biol Phys 72 Suppl. 2008 S30 S31
4. A.V. D'Amico, M.-H. Chen, and A.A. Renshaw Androgen suppression and radiation vs radiation alone for prostate cancer: A randomized trial JAMA 299 2008 289 295 (Pubitemid 351159365)
5. J.W. Denham, A. Steigler, and D.S. Lamb Short-term androgen deprivation and radiotherapy for locally advanced prostate cancer: Results from the Trans-Tasman Radiation Oncology Group 96-01 randomised controlled trial Lancet Oncol 6 2005 841 850 (Pubitemid 41614795)
6. G.E. Hanks, T.F. Pajak, and A. Porter Phase III trial of long-term adjuvant androgen deprivation after neoadjuvant hormonal cytoreduction and radiotherapy in locally advanced carcinoma of the prostate: The Radiation Therapy Oncology Group protocol 92-02 J Clin Oncol 21 2003 3972 3978 (Pubitemid 46606211)
7. C.A. Lawton, M. DeSilvio, and M. Roach III An update of the phase III trial comparing whole pelvic to prostate only radiotherapy and neoadjuvant to adjuvant total androgen suppression: Updated analysis of RTOG 94-13, with emphasis on unexpected hormone/ radiation interactions Int J Radiat Oncol Biol Phys 69 2007 646 655 (Pubitemid 47418390)
8. C.A. Lawton, K. Winter, and R. Byhardt Androgen suppression plus radiation versus radiation alone for patients with D1 (pN+) adenocarcinoma of the prostate (results based on a national prospective randomized trial, RTOG 85-31) Int J Radiat Oncol Biol Phys 38 1997 931 939 (Pubitemid 27353671)
9. J. Laverdiere, A. Nabid, and L.D. De Bedoya The efficacy and sequencing of a short course of androgen suppression on freedom from biochemical failure when administered with radiation therapy for T2-T3 prostate cancer J Urol 171 2004 1137 1140 (Pubitemid 38327543)
10. J. Laverdiere, J.L. Gomez, and L. Cusan Beneficial effect of combination hormone therapy administered prior and following external beam radiation therapy in localised prostate cancer Int J Radiat Oncol Biol Phys 37 1997 247 252 (Pubitemid 27138705)
11. M. Roach, K. Bae, and J. Speight Short-term neoadjuvant androgen deprivation therapy and external-beam radiotherapy for locally advanced prostate cancer: Long-term results of RTOG 8610 J Clin Oncol 26 2008 585 591 (Pubitemid 351264352)
12. M.V. Pilepich, K. Winter, and C.A. Lawton Androgen suppression adjuvant to definitive radiotherapy in prostate carcinoma - Long-term results of phase III RTOG 85-31 Int J Radiat Oncol Biol Phys 61 2005 1285 1290 (Pubitemid 40470408)
13. M.V. Pilepich, K. Winter, and M.J. John Phase III Radiation Therapy Oncology Group (RTOG) trial 86-10 of androgen deprivation adjuvant to definitive radiotherapy in locally advanced carcinoma of the prostate Int J Radiat Oncol Biol Phys 50 2001 1243 1252 (Pubitemid 32727802)
14. E.M. Horwitz, K. Bae, and G.E. Hanks Ten-year follow-up of radiation therapy oncology group protocol 92-02: A phase III trial of the duration of elective androgen deprivation in locally advanced prostate cancer J Clin Oncol 26 2008 2497 2504
15. M.V. Pilepich, W.T. Sause, and W.U. Shipley Androgen deprivation with radiation therapy compared with radiation therapy alone for locally advanced prostatic carcinoma: A randomized comparative trial of the Radiation Therapy Oncology Group Urology 45 1995 616 623
16. M. Gleave, L. Goldenberg, and E. Jones Biochemical and pathological effects of 8 months of neoadjuvant androgen withdrawal therapy before radical prostatectomy in patients with clinically confined prostate cancer J Urol 155 1996 213 219 (Pubitemid 126426468)
17. J.D. Cox, J. Stetz, and T.F. Pajak Toxicity criteria of the Radiation Therapy Oncology Group (RTOG) and the European Organization for Research and Treatment of Cancer (EORTC) Int J Radiat Oncol Biol Phys 31 1995 1341 1346
18. M. Zelefsky, S. Leibel, and J. Kutcher The feasibility of dose escalation of 3-dimensional conformal radiotherapy in patients with prostatic carcinoma Cancer J Sci Am 1 1995 142 150
19. American Society for Therapeutic Radiology and Oncology Consensus statement: Guideline for PSA following radiation therapy Int J Radiat Oncol Biol Phys 37 1997 1035 1041
20. T. Pickles, C. Kim-Sing, and W.J. Morris Evaluation of the Houston biochemical relapse definition in men treated with prolonged neoadjuvant and adjuvant androgen ablation and assessment of follow-up lead-time bias Int J Radiat Oncol Biol Phys 57 2003 11 18 (Pubitemid 36959733)
21. M. Roach, G. Hanks, and H. Thames Defining biochemical failure following radiotherapy with or without hormone therapy in men with clinically localized prostate cancer: Recommendations of the RTOG-ASTRO Phoenix consensus conference Int J Radiat Oncol Biol Phys 65 2006 965 974
22. National Comprehensive Cancer Network (NCCN) Clinical Practice Guidelines in Oncology™: Prostate Cancer (Version 1. 2008). Available at: http://www.nccn.org. Accessed November 12, 2008.
23. Cancer Therapy Evaluation Program Common terminology criteria for adverse events, version 3.0 2006 Division of Cancer Treatment and Diagnosis, National Cancer Institute, National Institutes of Health, Department of Health and Human Services Bethesda
24. E.L. Kaplan, and P. Meier Nonparametric estimation from incomplete observations J Am Stat Assoc 53 1958 457 481
25. J. Crook, C. Ludgate, and S. Malone Report of a multicenter Canadian phase III randomized trial of 3 months vs. 8 months neoadjuvant androgen deprivation before standard-dose radiotherapy for clinically localized prostate cancer Int J Radiat Oncol Biol Phys 60 2004 15 23 (Pubitemid 39165464)
26. J. Crook, C. Ludgate, and S. Malone Final report of multicenter Canadian phase III randomized trial of 3 versus 8 months of neoadjuvant androgen deprivation therapy before conventional-dose radiotherapy for clinically localized prostate cancer Int J Radiat Oncol Biol Phys 73 2009 327 333
27. W.C. Allsbrook, K.A. Mangold, and M.H. Johnson Interobserver reproducibility of Gleason grading of prostatic carcinoma: General pathologist Hum Pathol 32 2001 81 88 (Pubitemid 32150632)
28. W.C. Allsbrook, K.A. Mangold, and M.H. Johnson Interobserver reproducibility of Gleason grading of prostatic carcinoma: Urologic pathologists Hum Pathol 32 2001 74 80 (Pubitemid 32150631)
29. M. Mullerad, H. Hricak, and L. Wang Prostate cancer: Detection of extracapsular extension by genitourinary and general body radiologists at MR imaging Radiology 232 2004 140 146 (Pubitemid 38787829)
30. M.J. Zelefsky, M.W. Kattan, and P. Fearn Pretreatment nomogram predicting ten-year biochemical outcome of three-dimensional conformal radiotherapy and intensity modulated radiotherapy for prostate cancer Urology 70 2007 283 287 (Pubitemid 47362254)
31. A. Alexander, J. Crook, and S. Jones Is biochemical response more important than duration of neoadjuvant hormone therapy before radiotherapy for clinically localized prostate cancer? An analysis of the 3- versus 8-month randomized trial Int J Radiat Oncol Biol Phys 76 2010 23 30
32. J. Armstrong Three-dimensional conformal radiation therapy: Evidence-based treatment of prostate cancer Radiother Oncol 64 2002 235 237 (Pubitemid 35254016)
33. D.P. Dearnaley, M.R. Sydes, and J.D. Graham Escalated-dose versus standard-dose conformal radiotherapy in prostate cancer: First results from the MRC RT01 randomised controlled trial Lancet Oncol 8 2007 475 487 (Pubitemid 46805903)
34. A.L. Zietman, M.L. DeSilvio, and J.D. Slater Comparison of conventional-dose vs high-dose conformal radiation therapy in clinically localized adenocarcinoma of the prostate: A randomized controlled trial JAMA 294 2005 1233 1239 (Pubitemid 41352111)
35. A. Pollack, G.K. Zagars, and L.G. Smith Preliminary results of a randomized radiotherapy dose-escalation study comparing 70 Gy with 78 Gy for prostate cancer J Clin Oncol 18 2000 3904 3911
36. A. Pollack, G.K. Zagars, and G. Starkschall Prostate cancer radiation dose response: Results of the M.D. Anderson phase III randomized trial Int J Radiat Oncol Biol Phys 53 2002 1097 1105 (Pubitemid 34787842)
37. S.T. Peeters, W.D. Heemsbergen, and P.C. Koper Dose-response in radiotherapy for localized prostate cancer: Results of the Dutch multicenter randomized phase III trial comparing 68 Gy of radiotherapy with 78 Gy J Clin Oncol 24 2006 1990 1996 (Pubitemid 46622106)
38. O. Cahlon, M.J. Zelefsky, and A. Shippy Ultra-high dose (86.4 Gy) IMRT for localized prostate cancer: Toxicity and biochemical outcomes Int J Radiat Oncol Biol Phys 71 2008 330 337
39. S.L. Liauw, J. Fricano, and D. Correa Dose-escalated radiation therapy for intermediate-risk prostate cancer: Patient selection for androgen deprivation therapy using percentage of positive cores Cancer 115 2009 1784 1790
40. R. Malik, A.B. Jani, and S.L. Liauw PSA ''halving-time'' during neoadjuvant androgen deprivation therapy and prior to radiotherapy is associated with biochemical control [Abstract] Int J Radiat Oncol Biol Phys 72 Suppl. 2008 S56